

****Updated August 2014****

MarketVIEW: Cytomegalovirus vaccines (CAT: VAMV014)

Product Name	:	MarketVIEW: Cytomegalovirus vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 2 forecast models (.xls)
Therapeutic Area	:	Novel vaccines
Publication date	:	August 2014
Catalogue No	:	VAMV014

Background

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.

Vaccine manufacturers are currently pursuing both therapeutic (TX) and prophylatic (PX) CMV vaccine approaches. The most advanced program is Sanofi Pasteur's gB vaccine (+ MF59 adjuvant) where protective efficacy has been shown in post-partum women (Phase II) although development appears to be hold. Other notable approaches are Vical's (Astellas) VCL-CB01 (ASP0113) DNA-based approach in HSCT seropositive recipients (Phase III) to be completed September 2016.

This **MarketVIEW** product is composed of comprehensive MS Excel-based models + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. Each model contains value (\$ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. Two forecast scenarios are included based upon the level of populations targeted, differing competitive scenarios which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Cytomegalovirus vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published August 2014 (CAT No: VAMV014)

****This product is composed of two models (.xls) and summary presentation (.pdf)

Executive summary
Key model outputs
CMV preconception vaccine: available market (\$000s) to 2035 (scenario1)
CMV transplant vaccine: available market (\$000s) to 2035
CMV preconception vaccine: demand (000s doses) to 2035 (scenario1)
CMV transplant vaccine: demand (000s doses) to 2035
CMV preconception vaccine: available market (\$000s) to 2035 (scenario2)
CMV vaccines: revenues per company to 2035 (scenario 1)
CMV vaccines: revenues per company to 2035 (scenario 2)
CMV preconception vaccine: coverage scenarios
CMV vaccine: modelling assumptions/rationale
The role of CMV vaccine(s)
Target populations: CMV preconception vaccine
Target populations: CMV transplant vaccine
Target groups by serological risk profile
Pricing: CMV preconception vaccine
Pricing: CMV transplant vaccine
Target product profile: CMV preconception vaccine
Target product profile: CMV transplant vaccine
Key commercial model assumptions: preconception vaccine
Key commercial model assumptions: transplant vaccine
Markets included in the model
Model forecast comparisons: June 2010 v current
CMV vaccines: R&D pipeline
Competitor landscape: overview
Vical/Astellas: TransVax and CyMVectin
GSK: preconception CMV vaccine
Novartis/AlphaVax: alphavirus replicon CMV vaccine
Sanofi Pasteur: CMV gB vaccine
Merck & Co
Other vaccine candidates
Vaccine pipeline summary
Estimated launch dates: vaccines + mAbs
CMV: review of current epidemiology
Epidemiology: transplants

Epidemiology: congenital CMV infection
Appendix I: Quantifying CMV populations
Methodology: HSCTs populations (by age and serostatus)
Methodology: solid organ transplant populations (by age and serostatus)
Methodology: preconception vaccine
Other supporting data
Prevalence of CMV in the US general population
Prevalence of CMV in other general populations.
Prevalence of CMV in transplant donors and recipients
AIDS patients with CMV retinitis
Prevalence of CMV in pregnant populations
Symptomatic newborns
Management of CMV disease after solid organ transplantation
Management of CMV infection in HSCT
Use of prophylactic/pre-emptive antivirals in HSCTs
Management of CMV retinitis in patients with AIDS
Treatment of congenital CMV in newborns
References/bibliography
About **VacZine Analytics**
Disclaimer

PAGES: 86 slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based)

Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME – HIGH
VALUE SUMMARY
VOLUME SUMMARY
Preconception vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Transplant vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Source material

Continued.....

HSCTs by serostatus
Forecast HSCTs
Forecast HSCTs
Kidney and Liver TX base
Forecast Kidney TX
Forecast liver Tx
SOT by serostatus
Populations
Back page
About **VacZine Analytics**
Disclaimer

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$8995.00/ GBP £5620.00# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. US Department of Health and Human Services (HHS). Public Workshop - The Development and Evaluation of Human Cytomegalovirus Vaccines. 10-11 January 2012. Available at: <http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm280016.htm>. Accessed: May 2012
2. National Vital Statistics Reports, Volume 60, Number 1, November 3, 201.
3. Sabbaj S et al. CMV Glycoprotein B vaccine is capable of boosting both antibody and CD4 T cell responses to CMV in chronically infected women. *J Infect Dis*. 2011 Jun 1;203(11):1534-41.
4. Emery VC. Could a vaccine against immune-evading cytomegalovirus become a reality? *Expert Rev Vaccines*. 2011 Aug;10(8):1109-11.
5. Management of Cytomegalovirus in Transplant Recipients: Current Practice and Future Options. Available at: www.britjtransplant.com/backcopies/bjt5-roche.pdf. Accessed: May 2012
6. Dempsey AF et al. Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus. *Vaccine*. 2012 Apr 21. [Epub ahead of print]
7. Luan FL et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. *J Am Soc Nephrol*. 2009 Nov;20(11):2449-58.
8. TransVax™ Therapeutic CMV Vaccine. Available at: <http://www.vical.com/products/infectious-disease-vaccines/transvax/default.aspx>. Accessed: May 2012
9. Schleiss MR. Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission? *J Infect Dis*. 2011 Jun 1;203(11):1513-6.
10. Pass RF et al. Vaccine prevention of maternal cytomegalovirus infection. *N Engl J Med*. 2009 Mar 19;360(12):1191-9
11. Steining C. Cytomegalovirus vaccine: light on the horizon. *Lancet Infect Dis*. 2012 Apr;12(4):257-9.
12. Clinicaltrials.gov
13. Kharfan-Dabaja MA et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis* 2012; published online Jan 10. DOI:10.1016/S1473-3099(11)70344-9.
14. Novartis pipeline. Available at: <http://www.novartisvaccines.com/products-diseases/pipeline.shtml>. Accessed: May 2012
15. AlphaVax pipeline. Available at: <http://www.alphavax.com/products/pipeline.aspx> Accessed Feb 2014
16. Griffiths PD et al. Cytomegalovirus glycoprotein-B vaccine with MF-59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. *Lancet*. 2011 Apr 9;377(9773):1256-63.
17. Cayatee C et al. Cytomegalovirus vaccine strain town-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. *J. Virol*. 2013;87:11107
18. Fierce Biotech. Available at: <http://www.fiercevaccines.com/story/takeda-boehringer-invest-move-cmv-vaccine-clinic/2013-11-06> Accessed Feb 2014
19. Martín-Peña A et al. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. *Clin Transplant*. 2011 May-Jun;25(3):468-74.
20. Ljungman P et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. *Transplantation* 1998;66:1330-1334.
21. Ljungman P et al. Cytomegalovirus in hematopoietic stem cell transplant recipients. *Hematol Oncol Clin North Am*. 2011 Feb;25(1):151-69.
22. Rossini F et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. *Transpl Infect Dis*. 2005 Sep-Dec;7(3-4):122-5.
23. Emery VC et al. Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. *J Clin Virol*. 2012 Jun;54(2):125-9.
24. Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. *Transplantation*. 2008 Oct 27;86(8):1060-7.
25. Terlizzi ME et al. Monitoring of human Cytomegalovirus infection by antigenemia and viremia in the first 100 days following renal transplantation and relation to antiviral strategies. *Minerva Med*. 2008 Jun;99(3):231-9.
26. Hughes D et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. *J Clin Virol*. 2008 Feb;41(2):92-5.
27. Weikert BC et al. Viral infection after renal transplantation: surveillance and management. *Clin J Am Soc Nephrol*. 2008 Mar;3 Suppl 2:S76-86
28. Cannon MJ et al. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev. Med. Virol*. 20, 202-213 (2010)

29. Fowler KB et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. *N Engl J Med* 326:663-667, 1992
30. Cannon MJ. Congenital cytomegalovirus (CMV) epidemiology and awareness. *J. Clin. Virol.* 46(Suppl.), S6–S10 (2009).
31. Wang C et al. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. *Clin Infect Dis* 2011; 52:e11–e13
32. Yamamoto AY et al. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. *Pediatr Infect Dis J.* 2011 Dec;30(12):1043-6.
33. Joseph SA et al. Risk factors for cytomegalovirus seropositivity in a population of day care educators in Montréal, Canada. *Occup Med (Lond).* 2005 Oct;55(7):564-7.
34. Seale H et al. National serosurvey of cytomegalovirus in Australia. *Clin Vaccine Immunol.* 2006 Nov;13(11):1181-4.
35. Numazaki K et al. Relationship between seropositivity of husbands and primary cytomegalovirus infection during pregnancy. *J Infect Chemother.* 2000 Jun;6(2):104-6.
36. Picone O et al. A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. *BJOG.* 2009 May;116(6):818-23.
37. De Paschale M et al. Incidence and risk of cytomegalovirus infection during pregnancy in an urban area of Northern Italy. *Infect Dis Obstet Gynecol.* 2009;2009:206505.
38. Tookey PA et al. Cytomegalovirus prevalence in pregnant women: the influence of parity. *Arch Dis Child.* 1992 Jul;67(7 Spec No):779-83
39. Fang FQ et al. Incidence of cytomegalovirus infection in Shanghai, China. *Clin Vaccine Immunol.* 2009 Nov;16(11):1700-3.
40. Echániz-Avilés G et al. [Prevalence of antibodies against cytomegalovirus in women of reproductive age]. *Salud Publica Mex.* 1993 Jan-Feb;35(1):20-6.
41. Pasquini MC et al. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. Available at: <http://www.cibmtr.org>. Accessed: May 2012
42. Asia Pacific Blood and Marrow Transplantation Group (APBMT). Available at: <http://www.apbmt.org/>. Accessed May 2012
43. Organ Procurement and Transplantation Network. Available at: <http://optn.transplant.hrsa.gov/>. Accessed May 2012
44. Global Observatory of Donation and Transplantation. Available at: <http://www.transplant-observatory.org/>. Accessed May 2012
45. OPTN / SRTR 2010 Annual Data Report. HHS/HRSA/HSB/DOT. Available at: http://www.srtr.org/annual_reports/2010/. Accessed: May 2012
46. Annual HPV vaccine coverage in England in 2010/11. Available at: <http://immunisation.dh.gov.uk>. Accessed: May 2012
47. Limia A and Pachón I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. *Euro Surveill.* 2011; 16(21):pii=19873. Available online: www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19873
48. Blödt S et al. Human Papillomavirus awareness, knowledge and vaccine acceptance: A survey among 18-25 year old male and female vocational school students in Berlin, Germany. *Eur J Public Health.* 2011 Dec 23. [Epub ahead of print]
49. Fagot JP et al. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. *Vaccine.* 2011;29:3610–3616.
51. Widgren K et al. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. *Vaccine.* 2011 Dec 6;29(52):9663-7.
52. Marek E et al. Adolescents' awareness of HPV infections and attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine in Hungary. *Vaccine.* 2011 Nov 3;29(47):8591-8.
53. Chadenier GM et al. Assessment of the first HPV vaccination campaign in two northern Italian health districts. *Vaccine.* 2011 Jun 10;29(26):4405-8.
54. Bate SL et al. Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004. *Clin. Infect. Dis.* 2010;50:1439
55. De Ory F et al. Is there a change in cytomegalovirus seroepidemiology in Spain? *Eur. J. Epidemiol.* 2004;19:85
56. Lopo S et al. Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003. *Euro Surveill.* 2011;16(25):pii=19896
57. Gkrania-Klotsas E et al. Seropositivity and higher immunoglobulin G antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of cancer–Norfolk cohort. *Clin. Infect. Dis.* 2013;56:1421
58. Furui Y et al. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. *Transfusion.* 2013;53:2190
59. Enders G et al. Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010. *Med. Microbiol. Immunol.* 2012;201:303

60. Varga M et al. Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group. *Transplant. Proc.* 2011;43:1233
61. Khameneh ZR et al. Cytomegalovirus infection among Iranian kidney graft recipients. *Transplant. Proc.* 2013;45:178
62. AIDSinfo. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. 2013 <http://aidsinfo.nih.gov/guidelines> [Accessed Feb 2014]
63. Jabs DA et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. *Ophthalmology.* 2007;114:780
64. Sugar EA et al. Incidence of Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy. *Am. J. Ophthalmol.* 2012;153:1016
65. Pembrey L et al. Seroprevalence of Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus among Pregnant Women in Bradford: A Cohort Study. *PLoS. One.* 2013;8:e81881
66. Ikuta K et al. Cytomegalovirus (CMV) glycoprotein H-based serological analysis in Japanese healthy pregnant women, and in neonates with congenital CMV infection and their mothers. *J. Clin. Virol.* 2013;58:474
67. Taniguchi K et al. Changes in cytomegalovirus seroprevalence in pregnant Japanese women—A 10-year single center study. *J. Clin. Virol.* 2014 [Epub ahead of print]
68. Townsend CL et al. Surveillance of congenital cytomegalovirus in the UK and Ireland. *Arch. Dis. Child. Fetal. Neonatal. Ed.* 2011;96:F398
69. Andrews PA et al. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. *Transplantation* 2011;92:1181
70. Emery V et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. *Br. J. Haematol.* 2013;162:25
71. Pollack M et al. An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients. *Biol. Blood. Marrow. Transplant.* 2011;17:664
72. Kadambari S et al. Evidence based management guidelines for the detection and treatment of congenital CMV. *Early Hum. Dev.* 2011;87:723

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009